Voltaren Emulgel 20mg/g gel for external use

Country: Armenja

Lingwa: Ingliż

Sors: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Ingredjent attiv:

diclofenac (diclofenac diethylamine)

Disponibbli minn:

Novartis Consumer Health S.A.

Kodiċi ATC:

M02AA15

INN (Isem Internazzjonali):

diclofenac (diclofenac diethylamine)

Dożaġġ:

20mg/g

Għamla farmaċewtika:

gel for external use

Unitajiet fil-pakkett:

50g laminated tube, 100g laminated tube

Tip ta 'preskrizzjoni:

OTC

L-istatus ta 'awtorizzazzjoni:

Registered

Data ta 'l-awtorizzazzjoni:

2015-09-04

Fuljett ta 'informazzjoni

I
Bo.ru.rnpeH 3Mym.reJib
2%
renT>
p,!ISI
Hapy?KHoro
npHMeHeHHSI,
JIHCTOR- BlOPM~M.5I
,ZVI5I
ITA~MEHTOB)
TOPROSOE UA3SAUUENPENAPATA:
BOllhTAPE~
3MYnhrEnh®
ME)KJ.EYLLAPO,!L;UOE
UENATEHTOBAUUOE UA3BANUE:
.D:HKJioeuru<
JLEKAPCMEUUAN
C}JOPMA:
reJII,
.n;JUI
uapy)KHoro npHMeuemm
2%
COCTAB:
B
1
r npenapaTa
co.n;ep)I(HTC51:
BY
AKTUBHOE
BEM:ECTBO:
23,2Mr
,!I;HKJIOeHrueHruHH
)KH)l;KHH,
OJieHJIOBhiH
CUHp
T,
3BKaJIHITTOBa51
QT.n;ymKa,
6yTHJirH.n;pOKCHTOJIYOJI,
npOITHJieHrJIHKOJih,
BO)l;a
QqHII.(eHHM:
ONUCAUUE:
M51rKHH,
o.n;uopo.n;Hhlii,
KpeMoo6pa3Hhili reJih,
[(BeT
oT
6enoro
.!1:0
)l(eJITosaroro.
«J)APMAKOTEPANEBTUQECKAB
RPYNNA
Cpe.n;crsa
.
.n;Jl51
Hapy)KHoro
npHMeHeHH51
npH
6oJI5~X
B cycrasax H Mhiiiii.(ax.
HecrepoH.n;Hbie
npomsosocnanHTeJihHhie
cpe.n.crsa
.n;AA
Hap)')I(Horo
npHMeHeHH51.
KO).L.
ATX:
M02AA15
«J)APMAKOJIORUQECKUCCBOHCTBA
WAPMAKOTJ:HHAMUKA
,[{HKJioeHru<
uecrepoH.n;uoe
npoTHBopesMarHqecKoe
cpe.n;crno
c
Bhipa)l(eHHbiM
aHanbrern:qecKHM,
npoTHBOBOCITaJIHTeJihHhiM
H
:aeHrueuaKa,
scacbmaiOmeroc5~
qepe3
Ko~,
nponopuHoHaJibHO
nnoma.n:u
o6pa6arhmaeMoii
nosepxuocrH
H
3aBHCHT
I~
JJ;O~!?lJlaHOCRMO
npenapara,
Ta.K
H .
OT
CTeUeHH
m.n;paTffilHH
I

Aqra d-dokument sħiħ

Karatteristiċi tal-prodott

Novartis Consumer Health SA
CH-1260 Nyon, Switzerland
Global Regulatory Affairs
VOLTAREN ®EMULGEL®
Gel
Diclofenac diethylamine 2.32%
F.AADI01
REGIONAL SUMMARY OF PRODUCT CHARACTERISTICS (SMPC)
Property of Novartis Consumer Health
Confidential
May not be used, divulged, published or otherwise disclosed
without the consent of Novartis Consumer Health
Novartis Consumer Health SA
CONFIDENTIAL
Page 2
EU-rSmPC
Voltaren Forte 2.32% gel
TABLE OF CONTENTS
1
NAME OF THE MEDICINAL PRODUCT
.......................................................................
3
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
............................................. 3
3
PHARMACEUTICAL FORM
............................................................................................
3
4
CLINICAL PARTICULARS
..............................................................................................
3
4.1
Therapeutic indications
............................................................................................
3
4.2
Posology and method of administration
.................................................................. 3
4.3
Contraindications
.....................................................................................................
4
4.4
Special warnings and precautions for use
................................................................ 5
4.5
Interaction with other medicinal products and other forms of
interaction .............. 5
4.6
Pregnancy and lactation
...........................................................................................
5
4.7
Effects on ability to drive and use machines
........................................................... 5
4.8
Undesirable effects
..................................................................................................
5
4.9
Overdose
..................................................................................................................
6
5
PHARMACOLOGICAL PROPERTIES
............................................................................
6